Officials at Cytiva report that the company has completed an extensive renovation to its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, MA. The upgraded facility is 60,000 square feet and has bioprocessing capabilities ranging in scale from 10L to 2000L.

“Biotechnology companies are increasingly outsourcing their manufacturing, whether to access expertise, capacity, or both,” says Olivier Loeillot, senior vice president, bioprocess. “Our upgraded Fast Trak cGMP facility will provide our customers, particularly the small to mid-size companies, with the services and expertise needed to help expedite their processes and get to market faster.”

Biomanufacturers working with Fast Trak maintain control over their intellectual property and can place “people-in-plant” for full understanding of the process, adds Loeillot. The site utilizes Cytiva’s Figurate automation that includes control and communication capabilities which can turn “data insights into productive outcomes for both upstream and downstream processes efficiency gains,” continues Loeillot. Global Data reports that more than 70% of the clinical trials planned for the U.S. in 2020 will be Phase I and II, with over 50% of  companies outsourcing at least some bioprocessing, and 19% outsourcing more than half, according to BioPlan Associates.

Previous articleNew Research and Development Strategies in Virology/Viral Immunology
Next articleProtein and RNA Used to Create Vesicles for Potential Drug Delivery